Abstract
Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squa......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
